138 related articles for article (PubMed ID: 32790920)
1. Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses.
Pozzato G; Mazzaro C; Artemova M; Abdurakhmanov D; Grassi G; Crosato I; Mauro E; Ghersetti M; Zorat F; Bomben R; Bulian P; Gattei V
Br J Haematol; 2020 Dec; 191(5):775-783. PubMed ID: 32790920
[TBL] [Abstract][Full Text] [Related]
2. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
Gragnani L; Visentini M; Fognani E; Urraro T; De Santis A; Petraccia L; Perez M; Ceccotti G; Colantuono S; Mitrevski M; Stasi C; Del Padre M; Monti M; Gianni E; Pulsoni A; Fiorilli M; Casato M; Zignego AL
Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy.
Mazzaro C; Dal Maso L; Mauro E; Visentini M; Tonizzo M; Gattei V; Andreone P; Pozzato G
Autoimmun Rev; 2020 Aug; 19(8):102589. PubMed ID: 32540448
[TBL] [Abstract][Full Text] [Related]
5. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
[TBL] [Abstract][Full Text] [Related]
6. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Gragnani L; Fabbrizzi A; Triboli E; Urraro T; Boldrini B; Fognani E; Piluso A; Caini P; Ranieri J; Monti M; Laffi G; Zignego AL
Dig Liver Dis; 2014 Sep; 46(9):833-7. PubMed ID: 24953206
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.
Gragnani L; Fognani E; Piluso A; Boldrini B; Urraro T; Fabbrizzi A; Stasi C; Ranieri J; Monti M; Arena U; Iannacone C; Laffi G; Zignego AL;
Hepatology; 2015 Apr; 61(4):1145-53. PubMed ID: 25431357
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
Saadoun D; Thibault V; Si Ahmed SN; Alric L; Mallet M; Guillaud C; Izzedine H; Plaisier A; Fontaine H; Costopoulos M; Le Garff-Tavernier M; Hezode C; Pol S; Musset L; Poynard T; Cacoub P
Ann Rheum Dis; 2016 Oct; 75(10):1777-82. PubMed ID: 26567178
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy.
Mazzaro C; Bomben R; Gragnani L; Visentini M; Pozzato G; Pozzo F; Zucchetto A; Gattei V
Semin Hematol; 2022 Oct; 59(4):177-182. PubMed ID: 36805885
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.
Lauletta G; Russi S; Pavone F; Vacca A; Dammacco F
Arthritis Res Ther; 2017 Apr; 19(1):74. PubMed ID: 28388935
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus-associated non-Hodgkin lymphomas: the endless history.
Pozzato G; Mazzaro C; Gattei V
Minerva Med; 2021 Apr; 112(2):215-227. PubMed ID: 33263375
[TBL] [Abstract][Full Text] [Related]
12. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
Landau DA; Saadoun D; Halfon P; Martinot-Peignoux M; Marcellin P; Fois E; Cacoub P
Arthritis Rheum; 2008 Feb; 58(2):604-11. PubMed ID: 18240235
[TBL] [Abstract][Full Text] [Related]
13. miRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon-free antiviral therapy.
Peveling-Oberhag J; Bankov K; Dultz G; Ballo O; Lohmeyer J; Brunnberg U; Marcu V; Walter D; Zeuzem S; Hansmann ML; Welzel TM; Vermehren J
Antivir Ther; 2019; 24(6):437-442. PubMed ID: 31180334
[TBL] [Abstract][Full Text] [Related]
14. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.
Carrier P; Jaccard A; Jacques J; Tabouret T; Debette-Gratien M; Abraham J; Mesturoux L; Marquet P; Alain S; Sautereau D; Essig M; Loustaud-Ratti V
Liver Int; 2015 Oct; 35(10):2222-7. PubMed ID: 26104059
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study.
Cheng YT; Cheng JS; Lin CH; Chen TH; Lee KC; Chang ML
Clin Microbiol Infect; 2020 Mar; 26(3):366-372. PubMed ID: 31229596
[TBL] [Abstract][Full Text] [Related]
17. Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis.
Gragnani L; Cerretelli G; Lorini S; Steidl C; Giovannelli A; Monti M; Petraccia L; Sadalla S; Urraro T; Caini P; Xheka A; Simone A; Arena U; Matucci-Cerinic M; Vergani D; Laffi G; Zignego AL
Aliment Pharmacol Ther; 2018 Aug; 48(4):440-450. PubMed ID: 29952013
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
[TBL] [Abstract][Full Text] [Related]
19. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L
Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
